CSIMarket
 
Assembly Biosciences Inc   (ASMB)
Other Ticker:  
 

Assembly Biosciences Inc

Business Description


Assembly Biosciences Inc. is a biotechnology company that focuses on providing solutions for the treatment of hepatitis B virus (HBV) and other viral diseases. The company was founded in 2005 and is headquartered in South San Francisco, California.

Assembly Biosciences is primarily engaged in the development of small molecule antiviral drugs that target and inhibit the replication of viruses. Their approach involves using a proprietary technology platform called HBV-Core Inhibitor (or ABI-H0731) that specifically targets the core protein of the hepatitis B virus.

HBV is a persistent and complex viral infection that affects the liver and can lead to various complications, including liver cirrhosis and liver cancer. Despite the availability of vaccines, there is a significant unmet medical need for effective therapeutics that can achieve sustained viral suppression and potentially cure HBV.

The company*s lead product candidate, ABI-H0731, is currently being evaluated in clinical trials as a potential treatment for chronic HBV infection. It is an investigational drug designed to inhibit viral replication and reduce the level of virus in the body. Assembly Biosciences aims to develop ABI-H0731 as a cornerstone therapy for HBV, either as a monotherapy or in combination with other antiviral agents.

Assembly Biosciences also has a robust pipeline of other HBV core inhibitors, including ABI-H2158 and ABI-H3733. These compounds are in preclinical development and have shown encouraging preclinical data indicating their potential for high potency, low toxicity, and minimal resistance.

In addition to HBV, Assembly Biosciences is actively exploring the potential of its core inhibitor platform in other chronic viral infections, such as human papillomavirus (HPV) and Human Immunodeficiency Virus (HIV). The company believes that the core inhibitors have broad applicability as a novel therapeutic approach to combat various viral diseases.

Assembly Biosciences has a team of experienced scientists and researchers who specialize in antiviral drug discovery and development. The company leverages its expertise in virology, medicinal chemistry, and drug delivery to accelerate the development of innovative therapies.

Furthermore, Assembly Biosciences has established collaborations with leading academic institutions and pharmaceutical companies to complement its internal capabilities and expand its research and development efforts.

Overall, Assembly Biosciences Inc. is dedicated to advancing the field of antiviral therapy and addressing significant unmet medical needs in viral diseases, particularly in the treatment of hepatitis B virus. With its focus on innovative small molecule core inhibitors, the company is well-positioned to make a meaningful impact on the lives of patients worldwide.



View Company Supplier View Company Competition View Company Customers


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com